HNGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hinge Health Inc (HNGE) is a good buy for a beginner investor with a long-term strategy and an investment range of $50,000-$100,000. The company demonstrates strong financial growth, positive analyst sentiment, and expanding market opportunities. While technical indicators are neutral, the company's fundamentals and growth potential make it a solid long-term investment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 52.482, and moving averages are converging, suggesting no clear trend. Key support is at 43.434, and resistance is at 46.314. Overall, technical indicators are neutral.
Strong Q4 2025 financial performance with 45.60% YoY revenue growth, 18.36% YoY net income growth, and improved gross margins.
Expansion into adjacent markets like women's pelvic health, menopause, and fall prevention.
Positive analyst sentiment with multiple 'Buy' and 'Outperform' ratings and price targets averaging around $
Appointment of Tyler Sloat to the board, enhancing financial and operational management.
Neutral hedge fund and insider trading sentiment.
Lack of recent congress trading data.
Slight pre-market price decline of -1.94%.
In Q4 2025, Hinge Health reported revenue of $170.73M (+45.60% YoY), net income of $32.10M (+18.36% YoY), EPS of $0.40 (+14.29% YoY), and gross margin of 84.36% (+2.94% YoY). These results demonstrate strong growth and profitability.
Analysts are generally positive on Hinge Health, with most maintaining 'Buy' or 'Outperform' ratings. Price targets range from $50 to $70, with the most recent target being $55. Analysts highlight the company's leadership in digital musculoskeletal therapy, strong financials, and growth opportunities in new markets.
